Cantor Out Defending NewLink Genetics, Says indoximod Is Differentiated vs epacadostat in Response Rates In More Heavily Pretreated Patient Population; Thinks Assuming Failure Of indoximod May Be Premature, But Understands That Shares Are Likely Pressured